Participants in clinical trials are closely observed for potential adverse reactions, including gastrointestinal symptoms, changes in laboratory values, or unexpected systemic effects
By week 12, clinical trial data shows an average weight loss of 8.7% across all dose groups, with the 12mg group already approaching 10%
GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation
Other common side effects may include: Bloating Constipation Mild digestive discomfort Diarrhoea Injection site irritation These symptoms are often mild to moderate and may improve over time as the body adjusts
male, 60%) between cases (n=27) and controls (n=17)
That subjective ease is precisely why it is dangerous